Engineered virus targets Hard-to-Treat endometrial cancer in early trial
NCT ID NCT03120624
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This early-phase study tests a specially designed virus that can infect and kill cancer cells while leaving healthy cells alone. It is given intravenously to people with stage IV or recurrent endometrial cancer. The trial aims to find the safest dose and check for side effects, with some participants also receiving a second drug (ruxolitinib) to see if that helps the virus work better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ENDOMETRIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.